Description
Chemical Name: Sodium (E)-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)glycinate
CAS number 592542-60-4
Molecular Weight: 473.47 g/mol
Mechanism of Action: Rigosertib sodium is a non-ATP-competitive inhibitor that targets and suppresses multiple signaling pathways involved in cancer cell proliferation, such as PLK1, PI3K, and Src. It can induce apoptosis (programmed cell death) and cell cycle arrest in cancer cells.
Primary Use: It is an experimental chemotherapeutic agent studied for its potential to treat hematological malignancies and solid tumors, particularly myelodysplastic syndromes (MDS) and pancreatic cancer.
Other names: It is also known by its code designations, such as ON-01910 and Estybon.
